Literature DB >> 9583873

Increased expression of the novel molecule OX-2 is involved in prolongation of murine renal allograft survival.

R M Gorczynski1, Z Chen, X M Fu, H Zeng.   

Abstract

BACKGROUND: Portal venous (p.v.) peritransplant immunization with dendritic cells from bone marrow cultures, along with cyclosporine (10 mg/kg), produces antigen-specific increased renal allograft survival compared with recipients receiving intravenous (i.v.) immunization. Increased survival is associated with altered cytokine production from recipient T cells restimulated with donor antigen. We used a suppressive subtractive hybridization approach to explore a role in the regulation of transplant rejection for other genes differentially expressed after p.v. immunization.
METHODS: Subtractive hybridization was performed using tissue from p.v. and i.v. immunized mice and a novel polymerase chain reaction-based approach. A gene-bank search was used to identify the source of the differentially expressed cDNAs. One product, the mouse homologue of rat OX-2, was further analyzed using Western gels and FACS analysis of dendritic cells (NLDC145+) isolated from p.v.-immunized mice.
RESULTS: Eighty cDNA clones were obtained by suppressive subtractive hybridization. Differential expression was confirmed in Northern RNA blots. One clone showed sequence homology to a gene encoding a molecule on rat dendritic cells (MRC OX-2), with homology to genes encoding the costimulatory molecules CD80 (B7-1) and CD86 (B7-2). In p.v.-immunized mice, a monoclonal antibody to the rat OX-2 molecule identified, by Western blot analysis, increased expression of a molecule with molecular weight (43 kDa) analogous to rat MRC-OX-2; labels (by FACS analysis) indentified increased numbers of a population of cells staining with NLDC145; and blocks indentified increased graft survival.
CONCLUSION: Our data suggest that OX-2 is functionally important in the increased graft survival seen in p.v.-immunized mice receiving renal allografts.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9583873     DOI: 10.1097/00007890-199804270-00016

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  8 in total

Review 1.  Is the CD200/CD200 receptor interaction more than just a myeloid cell inhibitory signal?

Authors:  Konstantinos Minas; Janet Liversidge
Journal:  Crit Rev Immunol       Date:  2006       Impact factor: 2.214

2.  Myxoma virus M141R expresses a viral CD200 (vOX-2) that is responsible for down-regulation of macrophage and T-cell activation in vivo.

Authors:  Cheryl M Cameron; John W Barrett; Liying Liu; Alexandra R Lucas; Grant McFadden
Journal:  J Virol       Date:  2005-05       Impact factor: 5.103

3.  Kaposi's sarcoma-associated herpesvirus OX2 glycoprotein activates myeloid-lineage cells to induce inflammatory cytokine production.

Authors:  Young-Hwa Chung; Robert E Means; Joong-Kook Choi; Bok-Soo Lee; Jae U Jung
Journal:  J Virol       Date:  2002-05       Impact factor: 5.103

4.  Evidence of a role for CD200 in regulation of immune rejection of leukaemic tumour cells in C57BL/6 mice.

Authors:  R M Gorczynski; Z Chen; J Hu; Y Kai; J Lei
Journal:  Clin Exp Immunol       Date:  2001-11       Impact factor: 4.330

5.  Alternative splicing of CD200 is regulated by an exonic splicing enhancer and SF2/ASF.

Authors:  Zhiqi Chen; Xuezhong Ma; Jianhua Zhang; Jim Hu; Reginald M Gorczynski
Journal:  Nucleic Acids Res       Date:  2010-06-17       Impact factor: 16.971

6.  Serum-derived exosomes from mice with highly metastatic breast cancer transfer increased metastatic capacity to a poorly metastatic tumor.

Authors:  Reginald M Gorczynski; Nuray Erin; Fang Zhu
Journal:  Cancer Med       Date:  2016-01-04       Impact factor: 4.452

7.  Over-Expression of CD200 Protects Mice from Dextran Sodium Sulfate Induced Colitis.

Authors:  Zhiqi Chen; Kai Yu; Fang Zhu; Reginald Gorczynski
Journal:  PLoS One       Date:  2016-02-03       Impact factor: 3.240

8.  Overexpression of CD200 is a Stem Cell-Specific Mechanism of Immune Evasion in AML.

Authors:  Shelley Herbrich; Natalia Baran; Tianyu Cai; Connie Weng; Marisa J L Aitken; Sean M Post; Jared Henderson; Chunhua Shi; Guillame Richard-Carpentier; Guy Sauvageau; Keith Baggerly; Gheath Al-Atrash; R Eric Davis; Naval Daver; Dongxing Zha; Marina Konopleva
Journal:  J Immunother Cancer       Date:  2021-07       Impact factor: 13.751

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.